Open AccessThalassaemia is paradoxically associated with a reduced risk of in‐hospital complications and mortality in COVID‐19: Data from an international registry
Author(s) -
ElBattrawy Ibrahim,
Longo Filomena,
Núñez Gil Iván J.,
Abumayyaleh Mohammad,
Gianesin Barbara,
Estrada Vicente,
Aparisi Álvaro,
ArroyoEspliguero Ramón,
Balocco Manuela,
Barella Susanna,
Beccaria Andrea,
Bonetti Federico,
Casale Maddalena,
De michele Elisa,
Denotti Anna Rita,
Fidone Carmelo,
Fortini Monica,
Gamberini Maria Rita,
Graziadei Giovanna,
Lisi Roberto,
Massa Antonella,
Marcon Alessia,
Rubinski Bryan,
Miano Maurizio,
Motta Irene,
Pinto Valeria Maria,
Piperno Alberto,
Mariani Raffaella,
Putti Maria Caterina,
Quota Alessandra,
Ribersani Michela,
Marziali Marco,
Roberti Domenico,
Rosso Rosamaria,
Tartaglione Immacolata,
Vitucci Angelantonio,
Voi Vincenzo,
Zecca Marco,
Romero Rodolfo,
Marouneld Charbel,
FernándezRozas Inmaculada,
Espejo Carolina,
Marhaeni Wulandewi,
Garcia Aguado Marcos,
Cappellini Maria Domenica,
Perrotta Silverio,
De Franceschi Lucia,
Piga Antonio,
Forni Gian Luca,
Akin Ibrahim
Publication year - 2022
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.17026
Subject(s) - medicine , cohort , intensive care unit , thalassemia , splenectomy , intubation , blood transfusion , disease , hemosiderosis , pediatrics , mortality rate , cohort study , surgery , spleen
Although numerous patient‐specific co‐factors have been shown to be associated with worse outcomes in COVID‐19, the prognostic value of thalassaemic syndromes in COVID‐19 patients remains poorly understood. We studied the outcomes of 137 COVID‐19 patients with a history of transfusion‐dependent thalassaemia (TDT) and transfusion independent thalassaemia (TIT) extracted from a large international cohort and compared them with the outcomes from a matched cohort of COVID‐19 patients with no history of thalassaemia. The mean age of thalassaemia patients included in our study was 41 ± 16 years (48.9% male). Almost 81% of these patients suffered from TDT requiring blood transfusions on a regular basis. 38.7% of patients were blood group O. Cardiac iron overload was documented in 6.8% of study patients, whereas liver iron overload was documented in 35% of study patients. 40% of thalassaemia patients had a history of splenectomy. 27.7% of study patients required hospitalization due to COVID‐19 infection. Amongst the hospitalized patients, one patient died (0.7%) and one patient required intubation. Continuous positive airway pressure (CPAP) was required in almost 5% of study patients. After adjustment for age‐, sex‐ and other known risk factors (cardiac disease, kidney disease and pulmonary disease), the rate of in‐hospital complications (supplemental oxygen use, admission to an intensive care unit for CPAP therapy or intubation) and all‐cause mortality was significantly lower in the thalassaemia group compared to the matched cohort with no history of thalassaemia. Amongst thalassaemia patients in general, the TIT group exhibited a higher rate of hospitalization compared to the TDT group ( p = 0.001). In addition, the rate of complications such as acute kidney injury and need for supplemental oxygen was significantly higher in the TIT group compared to the TDT group. In the multivariable logistic regression analysis, age and history of heart or kidney disease were all found to be independent risk factors for increased in‐hospital, all‐cause mortality, whereas the presence of thalassaemia (either TDT or TIT) was found to be independently associated with reduced all‐cause mortality. The presence of thalassaemia in COVID‐19 patients was independently associated with lower in‐hospital, all‐cause mortality and few in‐hospital complications in our study. The pathophysiology of this is unclear and needs to be studied in vitro and in animal models.